BioAge Launches Phase 2 Trial of Oral NLRP3 Inhibitor to Treat Diabetic Eye Disease
BioAge's BGE-102, discovered through human aging research, enters a Phase 2 trial targeting NLRP3 inflammation to preserve vision in diabetic macular edema.
Summary
BioAge Labs has dosed the first patient in QUELL-DME, a Phase 2 trial of BGE-102, an oral daily pill that blocks the NLRP3 inflammasome protein. The drug was identified not through eye research but through analysis of human aging cohorts, where lower NLRP3 activity correlated with slower aging and longer life. NLRP3 drives inflammation linked to cardiovascular disease, metabolic disorders, neurodegeneration, and retinal disease. The trial enrolls roughly 180 adults with diabetic macular edema, testing the drug alone and alongside standard anti-VEGF eye injections. An oral pill could replace or reduce the burden of repeated eye injections that cause many patients to drop out of care. Topline results are expected in the second half of 2027.
Detailed Summary
BioAge Labs has initiated QUELL-DME, a Phase 2 clinical trial testing BGE-102, an oral NLRP3 inhibitor, in adults with diabetic macular edema — a leading cause of vision loss in working-age adults affecting roughly one million Americans. The drug's origins lie not in ophthalmology but in aging biology: BioAge's discovery platform identified NLRP3 as a longevity-relevant target by analyzing human aging cohorts and finding that people with lower NLRP3 activity tended to age more slowly and live longer.
NLRP3 sits at the top of a broad inflammatory cascade implicated in cardiovascular disease, obesity, metabolic dysfunction, neurodegeneration, and inflammation-driven eye diseases. In diabetic macular edema specifically, NLRP3 activation triggers IL-1β and IL-18 release, pyroptosis, VEGF production, and breakdown of the blood-retinal barrier — all contributing to fluid accumulation and blurred central vision.
The three-arm trial randomizes approximately 180 participants to: anti-VEGF injections plus placebo, anti-VEGF plus 90 mg BGE-102 daily, or sham injection plus 90 mg BGE-102 alone. This design allows researchers to evaluate the drug as both an add-on therapy and a standalone oral alternative. The primary endpoint is change in vision at 12 weeks. Topline results are anticipated in the second half of 2027.
The practical implication is significant. Current standard of care requires repeated intravitreal injections, which are uncomfortable and drive poor patient adherence. A once-daily oral pill, if effective, could dramatically lower that treatment barrier. BioAge also views QUELL-DME as a platform trial, with results expected to inform development for other NLRP3-driven retinal diseases like geographic atrophy.
Caveats remain: this is Phase 2, efficacy is unproven, and the article is a news report based on a company announcement rather than peer-reviewed data. Results are still more than a year away, and translation from aging-cohort biomarker data to clinical benefit requires rigorous confirmation.
Key Findings
- BGE-102 blocks NLRP3, an inflammasome protein linked to slower aging, cardiovascular disease, and retinal damage.
- QUELL-DME is a 180-person Phase 2 trial testing the drug alone and alongside standard anti-VEGF eye injections.
- BioAge discovered NLRP3 as a target through human aging cohort data, not traditional eye-disease research.
- An oral once-daily pill could replace painful repeated eye injections, improving patient adherence in DME.
- Results expected in second half of 2027 will also guide BGE-102 development for geographic atrophy.
Methodology
This is a news report based on a company press announcement from BioAge Labs regarding the initiation of a Phase 2 trial. No peer-reviewed data are yet available; the article summarizes trial design, mechanistic rationale, and executive statements. Source credibility is moderate — Longevity.Technology is an established longevity-focused outlet but the underlying evidence is commercial and pre-results.
Study Limitations
All claims derive from a company announcement; no trial data have been published or peer reviewed. Phase 2 trials frequently fail to replicate earlier promise, and the 12-week vision endpoint may not capture long-term benefit. The article does not report safety data, prior Phase 1 findings, or the statistical powering of the trial.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: